Enterin
Biotechnology, 2005 Market St Ste 3125, Philadelphia, Pennsylvania, 19103, United States, 11-50 Employees
Who is ENTERIN
Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical c...
Read More
-
Headquarters: 2005 Market St Ste 3125, Philadelphia, Pennsylvania, 19103, United States
-
Date Founded: 2016
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
Enterin Org Chart and Mapping
Email
Phone
Similar Companies to Enterin
Egalet Corporation
-
51-200
-
$ 25 Million to 50 Million
Merck
-
10001+
-
$ 1 Billion and Over
Parexel
-
10001+
-
$ 1 Billion and Over
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Enterin
Answer: Enterin's headquarters are located at 2005 Market St Ste 3125, Philadelphia, Pennsylvania, 19103, United States
Answer: Enterin's official website is https://enterininc.com
Answer: Enterin's revenue is $10 Million to $25 Million
Answer: Enterin's SIC: 2834
Answer: Enterin has 11-50 employees
Answer: Enterin is in Biotechnology
Answer: Enterin top competitors include: Egalet Corporation , Merck , Parexel
Answer: Enterin contact info: Phone number: Website: https://enterininc.com
Answer: Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. We are pioneering the medical communitys understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha-synuclein (S) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinsons disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinsons disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis and improve quality of life of patients with Parkinsons Disease and other neurodegenerative conditions.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month